Pacing

Pacing

Projects

DANPACE II

Atrial fibrillation (AF) is prevalent in a large proportion of patients with sick sinus syndrome (SSS) and is associated with an increased risk of thromboembolism. DANPACE II is a Danish multicentre randomised controlled trial (N=540) investigating whether reducing pacing rate to 40 bpm with the rate-response function off reduces the incidence of AF compared to conventional pacemaker programming at a lower pacing rate of 60 bpm and activated rate-response function in patients with SSS.

Clinicaltrials.gov identifier: NCT02034526

Leadless vs. RV pacing

ARTESiA – Apixaban for the Reduction of Thrombo-Embolism in patients with device-detected Sub-clinical Atrial fibrillation (SCAF)

Scroll to Top